Evotec Shares: A Fragile Rally Amid Deep-Seated Challenges

Evotec shares rebound 6% from lows but face sustained pressure. The firm forecasts a tough 2026 transition year with revenue decline and a major restructuring plan underway.

The stock of German biotechnology firm Evotec has shown tentative signs of life following a severe decline, with a recent rebound of approximately six percent. However, investors anticipating a swift and sustained recovery would be wise to consider the substantial operational hurdles the Hamburg-based company continues to face.

Trading at a closing price of 4.34 euros, the equity remains deeply in negative territory. It has shed more than 26 percent of its value in the past 30 days alone. From a technical perspective, the share is currently attempting to stabilize above its recently established 52-week low of 4.14 euros. While certain indicators suggest the stock is in an oversold condition, the broader picture on the weekly chart remains decidedly bearish. Market technicians argue that for any credible base formation to begin, the share price must first achieve a daily close above the near-term resistance level of 4.43 euros.

Fundamental Headwinds Drive the Downtrend

The persistent selling pressure is rooted in concrete fundamental issues. Evotec has explicitly designated 2026 as a transitional year, forecasting that revenue will fall to between 700 and 780 million euros. In a worst-case scenario, its adjusted EBITDA could contract to zero. The company's core drug discovery segment has been a particular area of weakness, recently posting a 13 percent drop in revenue.

Management is implementing aggressive countermeasures. A restructuring initiative, dubbed "Horizon," involves cutting up to 800 jobs and consolidating its global footprint to ten sites. This plan includes the complete closure of its Munich operations. The streamlining effort carries an upfront cost of around 100 million euros but is projected to yield annual savings of 75 million euros from late 2027 onward.

Positive Developments Fail to Impress the Market

The market's current hypersensitivity to operational weaknesses is evident in its reaction to ostensibly good news. Last week, Evotec secured a $10 million milestone payment from partner Bristol Myers Squibb. This payment was triggered by the initiation of a Phase 1 clinical trial for a promising cancer drug candidate from the "Molecular Glues" class. Yet, such strategic validations of the company's research pipeline are being either sold into or outright ignored by investors at present.

The next potential inflection point is already scheduled. On April 8, Evotec will release its final audited results for the previous fiscal year. Should the share price subsequently break below the critical support zone between 4.00 and 4.12 euros, it would likely trigger further technical selling, with analysts eyeing potential downside targets near the 3.82 euro mark.